HALO vs. PFE: Halozyme Therapeutics vs. Pfizer Stock Comparison
How do Halozyme Therapeutics (HALO) and Pfizer (PFE) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Halozyme Therapeutics (HALO) and Pfizer (PFE) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but HALO is classified in Biotechnology while PFE is classified in Pharmaceuticals.
| Profile Item | HALO | PFE |
|---|---|---|
| Name | Halozyme Therapeutics Inc. | Pfizer Inc. |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Pharmaceuticals |
| GICS Sub-Industry | Biotechnology | Pharmaceuticals |
| Market Capitalization | 11.81 billion USD | 167.52 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | NYSE |
| Listing Date | March 16, 2004 | June 1, 1972 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | HALO | PFE |
|---|---|---|
| Total Return (1Y) | 50.94% | 28.65% |
| Total Return (3Y, Annualized) | 41.08% | 6.41% |
| Total Return (5Y, Annualized) | 21.68% | -3.98% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | HALO | PFE |
|---|---|---|
| Volatility (1Y, Annualized) | 41.19% | 21.72% |
| Beta (5Y) | 0.96 | 0.35 |
| Max Drawdown (5Y) | -49.06% | -58.96% |
| Avg. Volume (3M) | 2.29M | 33.67M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | HALO | PFE |
|---|---|---|
| Sharpe Ratio (1Y) | 1.13 | 1.12 |
| Sortino Ratio (1Y) | 1.78 | 1.73 |
Profitability
ROE (TTM)
Halozyme Therapeutics (HALO) at 216.38% clears its industry range for ROE, a sharper capital-efficiency signal than Pfizer (PFE) at 4.47%, which is closer to a typical peer reading.
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
216.38%
- HALO
- 216.38%
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
PFE
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.47%
- Max
- 109.18%
- Q3
- 6.23%
- PFE
- 4.47%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Halozyme Therapeutics (HALO) at 26.93% keeps the most of each sales dollar — above its industry’s net margin range — and Pfizer (PFE) at 6.34% also retains a top-quartile share.
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
26.93%
- HALO
- 26.93%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
PFE
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.34%
- Max
- 18.05%
- PFE
- 6.34%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both Halozyme Therapeutics (HALO) at 59.84% and Pfizer (PFE) at 33.38% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
59.84%
- Max
- 83.12%
- HALO
- 59.84%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
PFE
Pharmaceuticals, Biotechnology & Life Sciences industry group
33.38%
- Max
- 83.12%
- PFE
- 33.38%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | HALO | PFE |
|---|---|---|
| ROE (TTM) | 216.38% | 4.47% |
| ROA (TTM) | 22.42% | 5.59% |
| Net Margin (TTM) | 26.93% | 6.34% |
| Operating Margin (TTM) | 59.84% | 33.38% |
| Gross Margin (TTM) | 77.74% | 74.90% |
Growth
Revenue Growth
Halozyme Therapeutics (HALO) at 37.55% is around its peer norm for revenue growth, while Pfizer (PFE) at -1.65% drops into the bottom quartile, signaling weaker demand or pricing momentum.
EPS Growth
Both Halozyme Therapeutics (HALO) at -25.36% and Pfizer (PFE) at -3.55% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.
Growth Metrics
| Metric | HALO | PFE |
|---|---|---|
| Revenue Growth (YoY) | 37.55% | -1.65% |
| Revenue Growth (3Y CAGR) | 28.38% | -14.80% |
| EPS Growth (YoY) | -25.36% | -3.55% |
| EPS Growth (3Y CAGR) | 21.14% | -37.12% |
Financial Strength
Current Ratio (MRQ)
Halozyme Therapeutics (HALO) at 3.88 keeps current ratio within its industry’s typical mid-range, while Pfizer (PFE) at 1.42 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for PFE.
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.88
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- HALO
- 3.88
- Q1
- 2.47
- Min
- 0.10
PFE
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.42
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- PFE
- 1.42
- Min
- 0.10
Debt / Equity (MRQ)
Only one side’s leverage can be read here: Pfizer (PFE) carries debt-to-equity ratio of 0.71 against its industry range, while Halozyme Therapeutics (HALO) reports no figure this period.
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
- HALO
- --
PFE
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.71
- Max
- 1.42
- PFE
- 0.71
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | HALO | PFE |
|---|---|---|
| Current Ratio (MRQ) | 3.88 | 1.42 |
| Debt / Equity (MRQ) | -- | 0.71 |
| Net Debt / EBITDA | 1.90 | 1.97 |
Dividends
Dividend Yield (TTM)
Halozyme Therapeutics (HALO) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Pfizer (PFE) reports a yield of 7.30%, ranking against industry peers normally.
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- HALO
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
PFE
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.30%
- PFE
- 7.30%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Pfizer (PFE) reports payout ratio above 100% at 245.71%, meaning dividends exceeded current-period earnings; Halozyme Therapeutics (HALO) pays no dividend (payout 0.00%).
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- HALO
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
PFE
Pharmaceuticals, Biotechnology & Life Sciences industry group
245.71%
- PFE
- 245.71%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | HALO | PFE |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 7.30% |
| Dividend Payout Ratio (TTM) | 0.00% | 245.71% |
Valuation
P/E Ratio (TTM)
Both Halozyme Therapeutics (HALO) at 25.91 and Pfizer (PFE) at 41.99 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
25.91
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- HALO
- 25.91
- Q1
- 13.30
- Min
- 0.07
PFE
Pharmaceuticals, Biotechnology & Life Sciences industry group
41.99
- Max
- 85.34
- Q3
- 43.46
- PFE
- 41.99
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
Pfizer (PFE) at 2.63 sits in the cheaper P/S ratio quartile while Halozyme Therapeutics (HALO) at 6.55 prices around its industry’s middle — PFE costs less per dollar of sales, though read it alongside growth and margins.
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.55
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- HALO
- 6.55
- Q1
- 3.01
- Min
- 0.01
PFE
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.63
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- PFE
- 2.63
- Min
- 0.01
P/B Ratio (MRQ)
Halozyme Therapeutics (HALO) reports a negative P/B ratio of -213.67, meaning negative book equity — the multiple itself is not meaningful for valuation. Meanwhile Pfizer (PFE) reports 1.88, ranking against industry peers normally.
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
-213.67
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
- HALO
- -213.67
PFE
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.88
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- PFE
- 1.88
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | HALO | PFE |
|---|---|---|
| P/E Ratio (TTM) | 25.91 | 41.99 |
| P/S Ratio (TTM) | 6.55 | 2.63 |
| P/B Ratio (MRQ) | -213.67 | 1.88 |
| Free Cash Flow Yield (TTM) | 3.48% | 7.76% |